Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 19 Dec 17

The "Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 16, 8, 39, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 3 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Human Papillomavirus (HPV) Associated Cancer - Overview
  3. Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development
  4. Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
  5. Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
  6. Human Papillomavirus (HPV) Associated Cancer - Drug Profiles
  7. Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
  8. Human Papillomavirus (HPV) Associated Cancer - Discontinued Products
  9. Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
  10. Appendix
  • Abion Inc
  • Admedus Ltd
  • Antigen Express Inc
  • Astex Pharmaceuticals Inc
  • Atara Biotherapeutics Inc
  • Bionor Pharma AS
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Formune SL
  • Genexine Inc
  • Hookipa Biotech AG
  • iBio Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • Iovance Biotherapeutics Inc
  • ISA Pharmaceuticals BV
  • Johnson & Johnson
  • Kite Pharma Inc
  • MedImmune LLC
  • Merck KGaA
  • NeoImmuneTech Inc
  • Onconova Therapeutics Inc
  • Oryx GmbH & Co KG
  • PDS Biotechnology Corp
  • Peregrine Pharmaceuticals Inc
  • Rottapharm Biotech Srl
  • Selecta Biosciences Inc
  • Shantha Biotechnics Pvt Ltd
  • Shuttle Pharmaceuticals LLC
  • Sirnaomics Inc
  • Transgene SA
  • UbiVac LLC
  • Vaccibody AS
  • VLPbio
  • Vyriad Inc

For more information about this report visit https://www.researchandmarkets.com/research/wcxss6/human?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20171219006054/en/

Business Wire
www.businesswire.com

Last updated on: 19/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.